相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Bortezomib as the First Proteasome Inhibitor Anticancer Drug: Current Status and Future Perspectives
D. Chen et al.
CURRENT CANCER DRUG TARGETS (2011)
Antitumor activity of an allosteric inhibitor of centromere-associated protein-E
Kenneth W. Wood et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Recent advances and method development for drug target identification
Janet N. Y. Chan et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2010)
Discovery and Exploitation of Inhibitor-resistant Aurora and Polo Kinase Mutants for the Analysis of Mitotic Networks
Paul J. Scutt et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
A molecular barcoded yeast ORF library enables mode-of-action analysis of bioactive compounds
Cheuk Hei Ho et al.
NATURE BIOTECHNOLOGY (2009)
Target profiling of small molecules by chemical proteomics
Uwe Rix et al.
NATURE CHEMICAL BIOLOGY (2009)
Identifying the proteins to which small-molecule probes and drugs bind in cells
Shao-En Ong et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Discovery and biochemical characterization of selective ATP competitive inhibitors of the human mitotic kinesin KSP
Keith W. Rickert et al.
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS (2008)
Molecular basis of bortezomib resistance:: proteasome subunit β5 (PSMB5) gene mutation and overexpression of PSMB5 protein
Ruud Oerlemans et al.
BLOOD (2008)
Molecular basis of drug resistance in Aurora kinases
Fiona Girdler et al.
CHEMISTRY & BIOLOGY (2008)
Point mutation of the proteasome β5 subunit gene is an important mechanism of bortezomib resistance in bortezomib-selected variants of Jurkat T cell lymphoblastic lymphoma/leukemia line
Shuqing Lu et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2008)
Selectivity-determining residues in Plk1
Michael Kothe et al.
CHEMICAL BIOLOGY & DRUG DESIGN (2007)
The small-molecule inhibitor BI 2536 reveals novel insights into mitotic roles of polo-like kinase 1
Peter Lenart et al.
CURRENT BIOLOGY (2007)
S-trityl-L-cysteine is a reversible, tight binding inhibitor of the human kinesin Eg5 that specifically blocks mitotic progression
Dimitrios A. Skoufias et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome
M Groll et al.
STRUCTURE (2006)
Identification of a novel synthetic thiazolidin compound capable of inducing c-Jun NH2-tkinase-dependent apoptosis in human colon cancer cells
F Teraishi et al.
CANCER RESEARCH (2005)
Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL
M Azam et al.
CELL (2003)
Paclitaxel Resistance: Molecular Mechanisms and Pharmacologic Manipulation
R. Z. Yusuf et al.
CURRENT CANCER DRUG TARGETS (2003)
Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification
ME Gorre et al.
SCIENCE (2001)
分享论文
